Do analysts rate CNTN or PMVP?

PMV Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 273.13%. Given PMV Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PMV Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has preferable earnings & valuation, CNTN or PMVP?

Hillstream Biopharma is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hillstream Biopharma N/A N/A -$35.92M -$1.15 N/A PMV Pharmaceuticals N/A N/A -$77.74M -$1.49 N/A

Is CNTN or PMVP more profitable?

Hillstream Biopharma's return on equity of -31.50% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Hillstream Biopharma N/A -31.50% -24.72% PMV Pharmaceuticals N/A -68.98% -62.70%

Does the media prefer CNTN or PMVP?

In the previous week, Hillstream Biopharma and Hillstream Biopharma both had 2 articles in the media. PMV Pharmaceuticals' average media sentiment score of 0.96 beat Hillstream Biopharma's score of 0.63 indicating that PMV Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hillstream Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PMV Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PMVP or VYGR?

In the previous week, Voyager Therapeutics had 2 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 4 mentions for Voyager Therapeutics and 2 mentions for PMV Pharmaceuticals. PMV Pharmaceuticals' average media sentiment score of 0.96 beat Voyager Therapeutics' score of 0.63 indicating that PMV Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PMV Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Voyager Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, TARA or PMVP?

Protara Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Protara Therapeutics N/A N/A -$57.44M -$1.34 N/A PMV Pharmaceuticals N/A N/A -$77.74M -$1.49 N/A

Is TARA or PMVP more profitable?

Protara Therapeutics' return on equity of -38.70% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Protara Therapeutics N/A -38.70% -36.02% PMV Pharmaceuticals N/A -68.98% -62.70%

Does the media prefer TARA or PMVP?

In the previous week, Protara Therapeutics had 1 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 3 mentions for Protara Therapeutics and 2 mentions for PMV Pharmaceuticals. PMV Pharmaceuticals' average media sentiment score of 0.96 beat Protara Therapeutics' score of 0.63 indicating that PMV Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PMV Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PMVP or OTLK more profitable?

Oncobiologics' return on equity of 0.00% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets PMV Pharmaceuticals N/A -68.98% -62.70% Oncobiologics N/A N/A -291.28%

Does the media refer more to PMVP or OTLK?

In the previous week, PMV Pharmaceuticals and PMV Pharmaceuticals both had 2 articles in the media. PMV Pharmaceuticals' average media sentiment score of 0.96 beat Oncobiologics' score of 0.93 indicating that PMV Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PMV Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncobiologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

PMV Pharmaceuticals (PMVP) Competitors

$1.34 +0.05 (+3.88%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$1.34 0.00 (0.00%)

As of 06/30/2026 07:34 PM Eastern

Compare

PMVP vs. CNTN, CHRS, VYGR, TARA, and OTLK

Should you buy PMV Pharmaceuticals stock or one of its competitors? MarketBeat compares PMV Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PMV Pharmaceuticals include Hillstream Biopharma (CNTN), Coherus Oncology (CHRS), Voyager Therapeutics (VYGR), Protara Therapeutics (TARA), and Oncobiologics (OTLK). These companies are all part of the "pharmaceutical products" industry.

How does PMV Pharmaceuticals compare to Hillstream Biopharma?

Hillstream Biopharma (NASDAQ:CNTN) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

PMV Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 273.13%. Given PMV Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Hillstream Biopharma's return on equity of -31.50% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-31.50%	-24.72%
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

Hillstream Biopharma is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A

1.2% of Hillstream Biopharma shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 3.3% of Hillstream Biopharma shares are owned by insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Hillstream Biopharma has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market.

In the previous week, Hillstream Biopharma and Hillstream Biopharma both had 2 articles in the media. PMV Pharmaceuticals' average media sentiment score of 0.96 beat Hillstream Biopharma's score of 0.63 indicating that PMV Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hillstream Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PMV Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

PMV Pharmaceuticals beats Hillstream Biopharma on 8 of the 13 factors compared between the two stocks.

How does PMV Pharmaceuticals compare to Coherus Oncology?

PMV Pharmaceuticals (NASDAQ:PMVP) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

PMV Pharmaceuticals presently has a consensus price target of $5.00, indicating a potential upside of 273.13%. Coherus Oncology has a consensus price target of $8.67, indicating a potential upside of 519.05%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Coherus Oncology is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, PMV Pharmaceuticals had 1 more articles in the media than Coherus Oncology. MarketBeat recorded 2 mentions for PMV Pharmaceuticals and 1 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 0.97 beat PMV Pharmaceuticals' score of 0.96 indicating that Coherus Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
PMV Pharmaceuticals	Positive
Coherus Oncology	Positive

Coherus Oncology has a net margin of 397.30% compared to PMV Pharmaceuticals' net margin of 0.00%. PMV Pharmaceuticals' return on equity of -68.98% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-68.98%	-62.70%
Coherus Oncology	397.30%	-198.90%	-46.65%

90.2% of PMV Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 7.6% of PMV Pharmaceuticals shares are owned by company insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Coherus Oncology has higher revenue and earnings than PMV Pharmaceuticals. PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A
Coherus Oncology	$42.17M	5.12	$168.02M	$1.67	0.84

PMV Pharmaceuticals has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Summary

Coherus Oncology beats PMV Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does PMV Pharmaceuticals compare to Voyager Therapeutics?

PMV Pharmaceuticals (NASDAQ:PMVP) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

90.2% of PMV Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 7.6% of PMV Pharmaceuticals shares are owned by insiders. Comparatively, 12.7% of Voyager Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Voyager Therapeutics had 2 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 4 mentions for Voyager Therapeutics and 2 mentions for PMV Pharmaceuticals. PMV Pharmaceuticals' average media sentiment score of 0.96 beat Voyager Therapeutics' score of 0.63 indicating that PMV Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PMV Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Voyager Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PMV Pharmaceuticals has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. Voyager Therapeutics' return on equity of -55.97% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-68.98%	-62.70%
Voyager Therapeutics	-319.61%	-55.97%	-43.12%

PMV Pharmaceuticals has higher earnings, but lower revenue than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A
Voyager Therapeutics	$40.37M	5.24	-$119.72M	-$1.97	N/A

PMV Pharmaceuticals has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market.

PMV Pharmaceuticals currently has a consensus price target of $5.00, suggesting a potential upside of 273.13%. Voyager Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 371.43%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Voyager Therapeutics is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Voyager Therapeutics beats PMV Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does PMV Pharmaceuticals compare to Protara Therapeutics?

Protara Therapeutics (NASDAQ:TARA) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Protara Therapeutics' return on equity of -38.70% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-38.70%	-36.02%
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

Protara Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A

Protara Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

In the previous week, Protara Therapeutics had 1 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 3 mentions for Protara Therapeutics and 2 mentions for PMV Pharmaceuticals. PMV Pharmaceuticals' average media sentiment score of 0.96 beat Protara Therapeutics' score of 0.63 indicating that PMV Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PMV Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by company insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Protara Therapeutics currently has a consensus target price of $26.25, suggesting a potential upside of 587.17%. PMV Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 273.13%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protara Therapeutics is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Protara Therapeutics beats PMV Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does PMV Pharmaceuticals compare to Oncobiologics?

PMV Pharmaceuticals (NASDAQ:PMVP) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Oncobiologics' return on equity of 0.00% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-68.98%	-62.70%
Oncobiologics	N/A	N/A	-291.28%

PMV Pharmaceuticals has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

PMV Pharmaceuticals presently has a consensus target price of $5.00, indicating a potential upside of 273.13%. Oncobiologics has a consensus target price of $6.50, indicating a potential upside of 308.81%. Given Oncobiologics' higher probable upside, analysts clearly believe Oncobiologics is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 7.6% of PMV Pharmaceuticals shares are held by company insiders. Comparatively, 1.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Oncobiologics has higher revenue and earnings than PMV Pharmaceuticals. Oncobiologics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A
Oncobiologics	$1.35M	175.01	-$62.42M	-$1.17	N/A

In the previous week, PMV Pharmaceuticals and PMV Pharmaceuticals both had 2 articles in the media. PMV Pharmaceuticals' average media sentiment score of 0.96 beat Oncobiologics' score of 0.93 indicating that PMV Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PMV Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncobiologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

PMV Pharmaceuticals beats Oncobiologics on 8 of the 13 factors compared between the two stocks.

Get PMV Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PMVP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PMVP vs. The Competition

Export

Metric	PMV Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$68.80M	$3.08B	$7.07B	$12.45B
Dividend Yield	N/A	1.86%	2.66%	6.16%
P/E Ratio	-0.90	19.38	27.25	24.87
Price / Sales	N/A	350.27	540.68	102.84
Price / Cash	N/A	57.53	48.53	58.59
Price / Book	0.68	4.28	11.01	6.54
Net Income	-$77.74M	$64.45M	$3.57B	$336.70M
7 Day Performance	13.56%	3.22%	2.31%	2.88%
1 Month Performance	8.94%	2.23%	1.39%	0.64%
1 Year Performance	27.62%	34.37%	36.71%	31.34%

PMV Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PMVP PMV Pharmaceuticals	3.4922 of 5 stars	$1.34 +3.9%	$5.00 +273.1%	+26.4%	$68.80M	N/A	N/A	50
CNTN Hillstream Biopharma	0.3691 of 5 stars	$3.35 -5.4%	N/A	N/A	$233.85M	N/A	N/A	2	News Coverage Gap Down High Trading Volume
CHRS Coherus Oncology	3.5516 of 5 stars	$1.48 +6.5%	$8.67 +485.6%	+91.4%	$228.29M	$46.88M	0.89	330
VYGR Voyager Therapeutics	3.6851 of 5 stars	$3.72 +2.8%	$16.50 +343.5%	+12.5%	$224.76M	$40.37M	N/A	100	News Coverage
TARA Protara Therapeutics	3.5155 of 5 stars	$3.98 -2.2%	$26.25 +559.5%	+26.1%	$223.68M	N/A	N/A	30	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PMVP) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PMV Pharmaceuticals (PMVP) Competitors

PMVP vs. CNTN, CHRS, VYGR, TARA, and OTLK

How does PMV Pharmaceuticals compare to Hillstream Biopharma?

Summary

How does PMV Pharmaceuticals compare to Coherus Oncology?

Summary

How does PMV Pharmaceuticals compare to Voyager Therapeutics?

Summary

How does PMV Pharmaceuticals compare to Protara Therapeutics?

Summary

How does PMV Pharmaceuticals compare to Oncobiologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMVP vs. The Competition

PMV Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PMV Pharmaceuticals (PMVP) Competitors

PMVP vs. CNTN, CHRS, VYGR, TARA, and OTLK

How does PMV Pharmaceuticals compare to Hillstream Biopharma?

Do analysts rate CNTN or PMVP?

Is CNTN or PMVP more profitable?

Which has preferable earnings & valuation, CNTN or PMVP?

Do insiders & institutionals hold more shares of CNTN or PMVP?

Which has more volatility and risk, CNTN or PMVP?

Does the media prefer CNTN or PMVP?

Summary

How does PMV Pharmaceuticals compare to Coherus Oncology?

Do analysts rate PMVP or CHRS?

Does the media refer more to PMVP or CHRS?

Is PMVP or CHRS more profitable?

Do institutionals and insiders have more ownership in PMVP or CHRS?

Which has higher earnings and valuation, PMVP or CHRS?

Which has more volatility & risk, PMVP or CHRS?

Summary

How does PMV Pharmaceuticals compare to Voyager Therapeutics?

Do institutionals & insiders hold more shares of PMVP or VYGR?

Does the media favor PMVP or VYGR?

Is PMVP or VYGR more profitable?

Which has higher valuation & earnings, PMVP or VYGR?

Which has more volatility and risk, PMVP or VYGR?

Do analysts rate PMVP or VYGR?

Summary

How does PMV Pharmaceuticals compare to Protara Therapeutics?

Is TARA or PMVP more profitable?

Which has better earnings and valuation, TARA or PMVP?

Which has more volatility & risk, TARA or PMVP?

Does the media prefer TARA or PMVP?

Do institutionals and insiders have more ownership in TARA or PMVP?

Do analysts rate TARA or PMVP?

Summary

How does PMV Pharmaceuticals compare to Oncobiologics?

Is PMVP or OTLK more profitable?

Which has more risk & volatility, PMVP or OTLK?

Do analysts rate PMVP or OTLK?

Do institutionals and insiders have more ownership in PMVP or OTLK?

Which has higher valuation and earnings, PMVP or OTLK?

Does the media refer more to PMVP or OTLK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMVP vs. The Competition

PMV Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools